Navigation Links
U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029
Date:4/14/2011

any has successfully conducted twelve clinical trials, including three pivotal Phase 3 studies.

Based on QRxPharma's recent pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA), the Company believes it is on track to file an NDA in mid-2011 for the use of MoxDuo IR in the management of moderate to severe acute pain.

About QRxPharma Limited

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to co-promote its products in the U.S. and seeks strategic partnerships for worldwide markets. QRxPharma's lead product candidate, immediate release MoxDuo, has successfully completed pivotal Phase 3 studies and the Company expects to file its New Drug Application (NDA) with the US Food and Drug Administration (FDA) in mid-2011. The Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo, as well as other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.

Forward Looking Statements

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-lookin
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
2. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
4. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
5. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
6. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
7. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
8. InNexus Biotechnology Strengthens Patent Team With New Leadership
9. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending PCT Shredder at the Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Rahal Letterman Lanigan Racing (RLL) ... blood stem cell banking and therapeutics, announced today that ... 16 Acorn Stairlifts Indy car driven by ... of the IZOD IndyCar 2013 season.   ... to support awareness of umbilical cord blood banking and ...
(Date:5/23/2013)... Calif. , May 23, 2013 ... a strategic alliance with DAK Renewable Research to ... corn oil yield. VG Energy is a majority ... Pink: VGLS). VG Energy,s exclusively licensed ... increase the oil yield in plants, possessing a ...
(Date:5/23/2013)... 23, 2013 BioTrends Research Group, one ... for specialized biopharmaceutical issues, finds that, unaided, one ... specialists reported that in the past six months, ... treatment) in anticipation of the next generation of ... when only 6 percent reported that they had ...
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... to Nearly $4 Million , , BETHPAGE, N.Y., ... largest private supporter of pancreatic cancer research, today announced its ... six leading research centers for early diagnostic tests and better ... , Lustgarten is expected to award nearly $4 million ...
... is designed to preserve the safety and integrity of ... June 23 CutisPharma, Inc. announced today that it ... the National Association of Boards of Pharmacy (NABP) for ... received accreditation for its Beverly facility. The NABP developed ...
... "By putting mutant genes from human patients into fruit ... this kind of neuromuscular disease," says Albena Jordanova. "Now ... behind Charcot-Marie-Tooth, as well as to start looking for ... the result of collaboration between VIB researchers working at ...
Cached Biology Technology:The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility 2Fruit fly steps in to fight human disease 2
(Date:5/23/2013)... mechanism by which estrogen suppresses lipid synthesis in the ... approach toward treating certain liver diseases. , With ... are changing long-held views in the field. Study results ... Science Signaling . , "The dogma in the ... only receptors located in the nucleus respond to steroid ...
(Date:5/23/2013)... 23, 2013) A new report from the Institute ... pupils engage in at least 60 minutes of vigorous ... No more than half of American youth meet current ... or moderate intensity physical activity daily, according to the ... are in school for nearly half of their waking ...
(Date:5/23/2013)... the interplay of brain chemicals which help us pay ... BBSRC. , By changing the way neurons respond ... these changes can affect the strength of a neuronal ... response. , Lead author Alex Thiele, Professor ... you can make yourself better heard by speaking louder ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide students with daily physical activity, IOM recommends 2
... identified a molecular pathway that plays a critical role ... only offers an important insight into the development of ... potential target for inhibiting the blood vessels that fuel ... The study, published online on Oct. 14 in ...
... Persons with multiple sclerosis who smoke risk increasing the ... and the subsequent severity of their disease, new research ... the University at Buffalo has shown. , The results ... and nonsmokers in 368 MS patients treated in UBs ...
... contemporary humans or an evolutionary side branch that eventually ... in human evolution as scientists explore the relationship of ... Two recent papers describing the sequencing of Neanderthal nuclear ... this question [1, 2]. However, the two studies came ...
Cached Biology News:Study reveals a key to blood vessel growth and possible drug target 2Study reveals a key to blood vessel growth and possible drug target 3Cigarette smoking may accelerate disability in those with MS 2
... new Finnigan Pocket Surveyor software provides ... existing Finnigan Surveyor HPLC Systems. The ... running the popular Windows Pocket PC ... ability to connect directly to their ...
... For separation and fractionation ... separation of nuclei from cytosolic ... sample complexity, greatly facilitating study ... of nucleic acid binding proteins ...
... an isotonic, balanced salt solution. It is routinely ... storage of whole blood at refrigerator temperatures for ... of blood is collected into a container of ... solution is placed in a refrigerator at 2-8 ...
... a fixative useful for routine procedures. Hollandes ... stable and will decalcify small bone specimens. ... be stained successfully with most stains, and ... red blood cell membranes and cosinophil and ...
Biology Products: